Good Participatory Practice (GPP) in research ensures respectful community engagement and strengthens trust through collaborative partnerships. 

The first edition of the Good Participatory Practice Guidelines for biomedical HIV prevention trials was published in 2007 by AVAC and UNAIDS. The GPP guidelines were created to provide a consistent global standard for stakeholder engagement across the research life-cycle and have since been adapted to benefit clinical research across fields, research areas, geographies and populations. 

The World Health Organization's Good Participatory Practice Guidelines for Emerging Pathogens (GPP-EP) were developed in 2016 to support prevention and treatment trials of emerging pathogens that were likely to cause severe disease outbreaks. The guidelines were adapted in 2020 specifically for COVID-19 to address how to engage community stakeholders and promote ethical standards throughout the research process: Good Participatory Practice for COVID-19 clinical trials: a toolbox

This page is for people who are designing and implementing COVID-19 or other rapid research studies and are looking for information on how to apply GPP effectively. It signposts to resources from other research areas (e.g. HIV and Ebola) which are generally applicable or adaptable to any disease or study.

BENEFITS OF GOOD PARTICIPATORY PRACTICE

GPP applies across research types and settings, and at all stages of research. There are many benefits including:

  • Strengthening the design, acceptability and quality of research as well as assessing feasibility of site selection
  • Strengthening recruitment and informed consent processes by incorporating local views and through dissemination of information
  • Identifying and minimising physical or social risks (e.g. community or individual stigma) that may result from enrolment
  • Strengthening alignment of research approaches and outcomes with the priorities of collaborating populations
  • GPP can empower communities and demonstrate respect, both as goals in themselves, and to strengthen mutual understanding, uptake of findings, trust and credibility of researchers with implications for current and future research 

GENERAL GUIDELINES & TOOLS

Good Participatory Practice (GPP) Guidelines

Community Engagement Guides

Risk Communication & Behaviour Change Resources

Monitoring & Evaluation

Training

Other Useful Resource Hubs

KEY CONSIDERATIONS

Ethics, Justice & Respect

Trust

Addressing Stigma

Social & Political considerations

Engagement at a distance

Mental Health & Gender-based violence

LEARNING FROM PAST PUBLIC HEALTH EMERGENCIES

Ebola virus disease

HIV/AIDS Research

APPLYING GPP TO EACH STAGE OF YOUR RESEARCH 

ADD YOUR RESOURCES

Please help the materials grow and evolve by sharing your resources related to Good Participatory Practices and Community Engagement in COVID-19 research. 

 

We would love to hear your reflections, experiences and learning. Please get in touch: mesh@tghn.org

Discover more about GPP in the context of engagement with vaccine research and development in the the Mesh theme area HERE

------------------------------------------------------------------------------------------------------------------------

This theme area has been created by: Lisa Schwartz; Nina GobatPhaikyeong CheahAlun Davies; John Marshall; Sassy Molyneux; Lina Moses; Noni Mumba; Srin Murthy; Elysée Nouvet; Beatriz Thome; Alexe Bernier; Zoha Salam with support from Anna Buhrmann and Helen Latchem

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License